Mustang Bio, Inc.
Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date
Seventeen of 18 patients with follow-up greater than 6 months achieved robust immune reconstitution
All 23 treated patients are alive and 20 patients with follow-up greater than 4 months recovered from pre-existing infections, are off protective isolation and prophylactic antimicrobials, and have normal growth velocity
WORCESTER, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on treatment with the same lentiviral vector used in MB-107, Mustangs lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease, in newly diagnosed infants under the age of two, were selected for an oral presentation during the Clinical Trials Spotlight Symposium at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19, 2022, both virtually and in Washington, D.C.
The presentation will include updated data from a multicenter Phase 1/2 clinical trial for XSCID in newly diagnosed infants under the age of two at St. Jude Childrens Research Hospital (St. Jude), UCSF Benioff Childrens Hospital in San Francisco and Seattle Childrens Hospital. The lentiviral gene therapy is also being assessed in a Phase 1/2 clinical trial at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for XSCID patients who have been previously treated with hematopoietic stem cell transplantation (HSCT) and for whom re-treatment is indicated.
The data include 23 infants with XSCID treated with the lentiviral vector at a median age of 3 months (range: 2.4-13.8) with a median follow-up of 2.4 years (range: 1.4 months to 5.4 years), making it the largest known cohort of infants treated with lentiviral (LV) gene therapy with the longest follow-up. Transduced autologous bone marrow CD34+ cells were generated for all patients with a median vector copy number (VCN) of 0.81/cell (range: 0.16-1.81), and a median CD34+ cell dose of 9.61x106/kg (range 4.4-18.95). Prior to the infusion of cells, patients received busulfan targeted to a cumulative area-under-the-curve (cAUC) of 22 mg*hr/L. All had hematopoietic recovery.
Story continues
Seventeen of 18 patients with a follow up of >6 months achieved robust immune reconstitution [median CD3+ 2,545/uL (range: 922-4,321), CD4+ 1,568/uL (range: 436-3,556), CD4+/CCR7+/CD45RO- 1,416/uL (range: 298-3,307)]. In these 17 patients, T cells matured appropriately as assessed by normal T cell receptor excision circles (TRECs) and TCRv repertoire diversity and were functional as judged by phytohemagglutinin activation. As presented previously in St. Judes 2019 New England Journal of Medicine paper (N Engl J Med 2019;380:1525-34.) and the accompanying Supplemental Appendix, the eighteenth patient achieved robust immune reconstitution as well following a gene therapy boost 12 months after the first infusion. Immunoglobulin replacement was discontinued in 15 patients, 12 have been immunized and two more have begun immunizations. Substantial multilineage engraftment occurred in all patients and was sustained over time as judged by VCN analysis in T, B, NK, and myeloid cells separated from peripheral blood. This analysis included 55 samples of 14 patients with 1.5 years of follow-up (VCN sample range: 1.5 to 5 years).
All treated patients are alive and 20 patients with a follow-up >4 months recovered from pre-existing infections, are off protective isolation and prophylactic antimicrobials, and have normal growth velocity. Identified integration site hotspots were consistent with previous reports for LV vectors, and no evidence of clonal expansion was observed.
Were looking forward to the upcoming presentation by St. Judes Dr. Ewelina Mamcarz at the ASGCT 25th Annual Meeting, as it will highlight updated data representing the largest cohort of infants with XSCID, also known as bubble boy disease, who have been treated with lentiviral gene therapy and the longest follow-up to date, said Manuel Litchman, M.D., President and Chief Executive Officer of Mustang. Mustang plans to initiate a multicenter pivotal Phase 2 trial for MB-107 under the Companys Investigational New Drug (IND) application in the second half of this year.
Details of the presentation are as follows:
Title: Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-Linked Severe Combined Immune Deficiency (XSCID) results in the Development of a Normal and Sustained Immune System: Interim Results of an ongoing Phase I/II Clinical StudySession: Clinical Trials Spotlight SymposiumDate and Time: Thursday, May 19, 8:45 9 a.m. ETPresenter: Ewelina Mamcarz, M.D., Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Childrens Research Hospital, Memphis, TN
For more information about the ASGCT 25th Annual Meeting, please visit: https://annualmeeting.asgct.org
About X-linked Severe Combined Immunodeficiency (XSCID)X-linked severe combined immunodeficiency is characterized by the absence or lack of function of key immune cells, resulting in a severely compromised immune system and death by 1 year of age if untreated. Patients with XSCID have no T-cells or natural killer (NK) cells. Although their B-cells are normal in number, they are not functional. As a result, XSCID patients are usually affected by severe bacterial, viral or fungal infections early in life and often present with interstitial lung disease, chronic diarrhea and failure to thrive. Among patients who receive allogeneic hematopoietic stem cell transplant (HSCT), many are unable to establish adequate T-cell immunity or lose T-cell immunity over time. Further, approximately two-thirds of patients who receive HSCT lack sufficient B-cell immunity and need lifelong immunoglobulin replacement therapy. XSCID is a rare genetic disorder that occurs in approximately 1 per 225,000 births. There are approximately 2,800 patients with XSCID worldwide who have been previously treated with HSCT, and who therefore might be eligible for gene therapy now or in the future.
The specific genetic disorder that causes XSCID is a mutation in the gene coding for the common gamma chain (c), a protein that is shared by the receptors for at least six interleukins. These interleukins and their receptors are critical for the development and differentiation of immune cells. The gene coding for c is known as IL-2 receptor gamma, or IL2RG. Because IL2RG is located on the X-chromosome, XSCID is inherited in an X-linked recessive pattern, resulting in almost all patients being male.
About Mustang BioMustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (SEC). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit http://www.mustangbio.com.
ForwardLooking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contacts:Jaclyn Jaffe and Bill BegienMustang Bio, Inc.(781) 652-4500ir@mustangbio.com
Investor Relations Contact:Daniel FerryLifeSci Advisors, LLC(617) 430-7576daniel@lifesciadvisors.com
Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com
- 001 Faulty Circuits (preview) [Last Updated On: April 7th, 2010] [Originally Added On: April 7th, 2010]
- 002 Faulty Circuits (preview) [Last Updated On: April 7th, 2010] [Originally Added On: April 7th, 2010]
- 003 Rare flowers and common herbal supplements get unmasked with plant DNA barcoding [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- 004 Rare flowers and common herbal supplements get unmasked with plant DNA barcoding [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- 005 Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 006 Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 007 Schizophrenia shares genetic links with autism, genome study shows [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 008 Schizophrenia shares genetic links with autism, genome study shows [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 009 Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: May 28th, 2010] [Originally Added On: May 28th, 2010]
- 010 Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: May 28th, 2010] [Originally Added On: May 28th, 2010]
- 011 Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 012 Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 013 Cancer Therapy Goes Viral: Progress Is Made Tackling Tumors with Viruses [Last Updated On: June 24th, 2010] [Originally Added On: June 24th, 2010]
- 014 Cancer Therapy Goes Viral: Progress Is Made Tackling Tumors with Viruses [Last Updated On: June 24th, 2010] [Originally Added On: June 24th, 2010]
- 015 Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: June 26th, 2010] [Originally Added On: June 26th, 2010]
- 016 Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: June 26th, 2010] [Originally Added On: June 26th, 2010]
- 017 A genome story: 10th anniversary commentary by Francis Collins [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 018 A genome story: 10th anniversary commentary by Francis Collins [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 019 Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: June 30th, 2010] [Originally Added On: June 30th, 2010]
- 020 Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: June 30th, 2010] [Originally Added On: June 30th, 2010]
- 021 DNA Drugs Come of Age (preview) [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 022 DNA Drugs Come of Age (preview) [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 023 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: July 22nd, 2010] [Originally Added On: July 22nd, 2010]
- 024 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: July 22nd, 2010] [Originally Added On: July 22nd, 2010]
- 025 Stem Cells from Reprogrammed Adult Cells Found to Bring Along Genetic Defects of Their Donors [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 026 Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 027 Parkinsonian Power Failure: Neuron Degeneration May Be Caused by a Cellular Energy System Breakdown [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 028 Stem Cells from Reprogrammed Adult Cells Found to Bring Along Genetic Defects of Their Donors [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 029 Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 030 Parkinsonian Power Failure: Neuron Degeneration May Be Caused by a Cellular Energy System Breakdown [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 031 Desperation Drives Parents to Dubious Autism Treatments (preview) [Last Updated On: October 13th, 2010] [Originally Added On: October 13th, 2010]
- 032 Desperation Drives Parents to Dubious Autism Treatments (preview) [Last Updated On: October 17th, 2010] [Originally Added On: October 17th, 2010]
- 033 Revolution Postponed: Why the Human Genome Project Has Been Disappointing (preview) [Last Updated On: October 21st, 2010] [Originally Added On: October 21st, 2010]
- 034 Controlling the Brain with Light (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 035 Optogenetics: Controlling the Brain with Light [Extended Version] [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 036 Clear New Insights into the Genetics of Depression [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 037 TEDMED 2010: Technology and the people [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 038 Bacteria, the anti-cancer soldier [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 039 Revolution Postponed: Why the Human Genome Project Has Been Disappointing (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 040 Controlling the Brain with Light (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 041 Optogenetics: Controlling the Brain with Light [Extended Version] [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 042 Clear New Insights into the Genetics of Depression [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 043 TEDMED 2010: Technology and the people [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 044 Bacteria, the anti-cancer soldier [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 045 Scientific regress: When science goes backward [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 046 Can You Live Forever? Maybe Not--But You Can Have Fun Trying [Last Updated On: January 1st, 2011] [Originally Added On: January 1st, 2011]
- 047 How to Fix the Obesity Crisis (preview) [Last Updated On: January 22nd, 2011] [Originally Added On: January 22nd, 2011]
- 048 Scientific regress: When science goes backward [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 049 Can You Live Forever? Maybe Not--But You Can Have Fun Trying [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 050 How to Fix the Obesity Crisis (preview) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 051 Personalizing cancer medicine [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 052 New Salmonella strain delivers gene-based therapy to fight virus in mice [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 053 Personalizing cancer medicine [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 054 New Salmonella strain delivers gene-based therapy to fight virus in mice [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 055 Steps toward a Bionic Eye [Last Updated On: February 18th, 2011] [Originally Added On: February 18th, 2011]
- 056 Steps toward a Bionic Eye [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 057 Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 058 Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 059 Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 060 Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 061 New Drugs for Hepatitis C on the Horizon [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 062 Can we capture all of the world's carbon emissions? [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 063 New Drugs for Hepatitis C on the Horizon [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 064 Can we capture all of the world's carbon emissions? [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 065 Drug-resistant genes found in cholera and dysentery strains in New Delhi water supply [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 066 Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview) [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 067 Drug-resistant genes found in cholera and dysentery strains in New Delhi water supply [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 068 Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview) [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 069 Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 070 A New Look at Obsessive-Compulsive Disorder (preview) [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 071 Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 072 A New Look at Obsessive-Compulsive Disorder (preview) [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 073 Close Encounters of Science and Medicine [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 074 Close Encounters of Science and Medicine [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 075 New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- 076 New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- 077 A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview) [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- 078 A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview) [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- 079 Gene therapy improves stem cell transplantation - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 080 THE NEW MORGELLONS HAIR - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]